{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:45:44Z","timestamp":1790711144596,"version":"4.1.0"},"reference-count":38,"publisher":"The Endocrine Society","issue":"10","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the association of long-term, continuous tirzepatide use with cardiometabolic risk parameters and estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk in real-world practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective observational study included 1028 adults with overweight or obesity who received weekly subcutaneous tirzepatide for at least 12 months within the Mayo Clinic Health System from June 2022 through May 2024. Atherosclerotic cardiovascular disease risk analyses included 275 individuals with complete baseline and 12-month follow-up data. Outcomes were changes in cardiometabolic parameters, estimated 10-year ASCVD risk, and ASCVD risk category.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 12 months, median total body weight loss (TBWL) was 12.6%. Fasting glucose, HbA1c, triglycerides, and alanine aminotransferase decreased by 19.5%, 16.0%, 8.5%, and 10.6%, respectively, whereas HDL-cholesterol increased by 11.3% (all P \u00a0&amp;lt; .001). Mean 10-year ASCVD risk did not change significantly overall (mean relative change, \u22123.7%; P = .18), but changes differed by TBWL category (analysis of variance, P \u00a0&amp;lt; .001). Atherosclerotic cardiovascular disease risk decreased among individuals achieving 10% to 20% TBWL (\u22129.6%; P = .009) and &amp;gt;20% TBWL (\u221214.2%; P = .005), but not among those achieving &amp;lt;10% TBWL (+7.7%; P = .22). Low-risk prevalence increased from 38.3% to 46.4% (P \u00a0&amp;lt; .001), with 11.7% transitioning from higher-risk categories to low risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main findings<\/jats:title>\n                    <jats:p>Continuous tirzepatide use for at least 12 months was associated with clinically meaningful improvements in cardiometabolic parameters. Reductions in estimated 10-year ASCVD risk were observed among individuals achieving at least 10% TBWL, supporting greater weight loss as an important marker of cardiovascular risk improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvag210","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:13:41Z","timestamp":1788948821000},"source":"Crossref","is-referenced-by-count":1,"title":["Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3349-3676","authenticated-orcid":false,"given":"Rene de J","family":"Rivera Gutierrez","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Mayo Clinic , Jacksonville, FL 32224 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4735-6609","authenticated-orcid":false,"given":"Regina","family":"Castaneda","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Mayo Clinic , Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7243-4663","authenticated-orcid":false,"given":"Alfredo","family":"Verastegui","sequence":"additional","affiliation":[{"name":"Division of Surgical Oncology, Mayo Clinic , Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9389-6795","authenticated-orcid":false,"given":"Wissam","family":"Ghusn","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9585-5111","authenticated-orcid":false,"given":"Dima","family":"Bechenati","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Mayo Clinic , Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-6210","authenticated-orcid":false,"given":"Maria A","family":"Espinosa","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-2527","authenticated-orcid":false,"given":"Jose","family":"Villamarin","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7595-9113","authenticated-orcid":false,"given":"Elif","family":"Tama","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Wayne State University, Henry Ford Rochester Hospital , Rochester, MI 48307, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7941-0824","authenticated-orcid":false,"given":"Kirsten","family":"Frederiksen","sequence":"additional","affiliation":[{"name":"Department of Surgery, Mayo Clinic , Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-489X","authenticated-orcid":false,"given":"Andres","family":"Acosta","sequence":"additional","affiliation":[{"name":"Precision Medicine for Obesity Program, Division of Gastroenterology and Hepatology, Mayo Clinic , Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2322-7334","authenticated-orcid":false,"given":"Maria D","family":"Hurtado Andrade","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Mayo Clinic , Jacksonville, FL 32224 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"3","key":"2026092905162960600_bvag210-B1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10469","key":"2026092905162960600_bvag210-B2","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/S0140-6736(24)01548-4","article-title":"National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050","volume":"404","author":"GBD 2021 US Obesity Forecasting Collaborators","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"2026092905162960600_bvag210-B3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","article-title":"Association of body mass Index with lifetime risk of cardiovascular disease and compression of morbidity","volume":"3","author":"Khan","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"2026092905162960600_bvag210-B4","doi-asserted-by":"crossref","first-page":"e023667","DOI":"10.1161\/JAHA.121.023667","article-title":"Body mass index and association with cardiovascular outcomes in patients with stable coronary heart disease - a STABILITY substudy","volume":"11","author":"Held","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"2026092905162960600_bvag210-B5","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.1016\/S2468-2667(17)30074-9","article-title":"Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe","volume":"2","author":"Kivim\u00e4ki","year":"2017","journal-title":"Lancet Public Health"},{"issue":"8","key":"2026092905162960600_bvag210-B6","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/ATVBAHA.118.311421","article-title":"Emerging roles for adipose tissue in cardiovascular disease","volume":"38","author":"Ha","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2026092905162960600_bvag210-B7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41569-018-0097-6","article-title":"The role of adipose tissue in cardiovascular health and disease","volume":"16","author":"Oikonomou","year":"2019","journal-title":"Nat Rev Cardiol"},{"issue":"11","key":"2026092905162960600_bvag210-B8","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCRESAHA.115.306885","article-title":"Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease","volume":"118","author":"Fuster","year":"2016","journal-title":"Circ Res"},{"issue":"2","key":"2026092905162960600_bvag210-B9","doi-asserted-by":"crossref","first-page":"e000582","DOI":"10.1161\/JAHA.113.000582","article-title":"Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations","volume":"3","author":"Fitzgibbons","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"2026092905162960600_bvag210-B10","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"issue":"9","key":"2026092905162960600_bvag210-B11","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.3390\/ijms20092358","article-title":"Adipose tissue dysfunction as determinant of obesity-associated metabolic complications","volume":"20","author":"Longo","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"10","key":"2026092905162960600_bvag210-B12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11883-021-00953-0","article-title":"Obesity management in cardiometabolic disease: state of the art","volume":"23","author":"Iwamoto","year":"2021","journal-title":"Curr Atheroscler Rep"},{"issue":"7","key":"2026092905162960600_bvag210-B13","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat Rev Cardiol"},{"issue":"4","key":"2026092905162960600_bvag210-B14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"2026092905162960600_bvag210-B15","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"2026092905162960600_bvag210-B16","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"2026092905162960600_bvag210-B17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10295","key":"2026092905162960600_bvag210-B18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2026092905162960600_bvag210-B19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/dom.15318","article-title":"Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis","volume":"26","author":"Hankosky","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2026092905162960600_bvag210-B20","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab Syndr"},{"issue":"25 Suppl 2","key":"2026092905162960600_bvag210-B21","first-page":"S49","article-title":"2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"129","author":"Goff","year":"2014","journal-title":"Circulation"},{"key":"2026092905162960600_bvag210-B22","doi-asserted-by":"crossref","first-page":"100335","DOI":"10.1016\/j.ajpc.2022.100335","article-title":"Atherosclerotic cardiovascular disease risk assessment: an American society for preventive cardiology clinical practice statement","volume":"10","author":"Wong","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"2026092905162960600_bvag210-B23","doi-asserted-by":"crossref","unstructured":"Rivera Gutierrez RdJ, Castaneda R, Verastegui A, et al \u00a02026. Supplementary material for \u201cCardiometabolic and ASCVD Outcomes Associated with Tirzepatide: Insights from a 1-Year Multicenter Observational Study\u201d. Zenodo. 10.5281\/zenodo.22030920.","DOI":"10.1210\/jendso\/bvag210"},{"issue":"6","key":"2026092905162960600_bvag210-B24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"2026092905162960600_bvag210-B25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-025-00767-4","article-title":"Effect of tirzepatide on cardiovascular outcomes","volume":"26","author":"Huston","year":"2026","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10313","key":"2026092905162960600_bvag210-B26","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","article-title":"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial","volume":"398","author":"Del Prato","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2026092905162960600_bvag210-B27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"2026092905162960600_bvag210-B28","doi-asserted-by":"crossref","first-page":"oeaf117","DOI":"10.1093\/ehjopen\/oeaf117","article-title":"Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial","volume":"5","author":"Mamas","year":"2025","journal-title":"Eur Heart J Open"},{"issue":"1","key":"2026092905162960600_bvag210-B29","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12933-025-02840-3","article-title":"Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety","volume":"24","author":"Tang","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"2026092905162960600_bvag210-B30","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s13300-025-01784-x","article-title":"Can dual incretin receptor agonists exert better cardiovascular protection than selective GLP-1 receptor agonists? Highlights from SURPASS-CVOT","volume":"16","author":"Fadini","year":"2025","journal-title":"Diabetes Ther"},{"issue":"7","key":"2026092905162960600_bvag210-B31","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"issue":"11","key":"2026092905162960600_bvag210-B32","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.eprac.2025.07.017","article-title":"American Association of Clinical Endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity\/adiposity-based chronic disease \u2013 2025 update","volume":"31","author":"Nadolsky","year":"2025","journal-title":"Endocr Pract"},{"issue":"8","key":"2026092905162960600_bvag210-B33","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.7326\/ANNALS-24-02623","article-title":"Improvements in cardiometabolic risk factors by weight reduction: a post hoc analysis of adults with obesity randomly assigned to tirzepatide","volume":"178","author":"Linetzky","year":"2025","journal-title":"Ann Intern Med"},{"issue":"7","key":"2026092905162960600_bvag210-B34","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/oby.23773","article-title":"The effect of weight loss on whole-body and tissue-specific insulin sensitivity and hepatic lipid content and composition: SWEET substudy","volume":"31","author":"Pang","year":"2023","journal-title":"Obesity"},{"issue":"10","key":"2026092905162960600_bvag210-B35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1055\/a-2266-1503","article-title":"The pathophysiological associations between obesity, NAFLD, and atherosclerotic cardiovascular diseases","volume":"56","author":"Li","year":"2024","journal-title":"Horm Metab Res"},{"issue":"17","key":"2026092905162960600_bvag210-B36","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/eurjpc\/zwac187","article-title":"Obesity and cardiovascular disease: mechanistic insights and management strategies. A joint position paper by the World Heart Federation and World Obesity Federation","volume":"29","author":"Lopez-Jimenez","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"2026092905162960600_bvag210-B37","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2026092905162960600_bvag210-B38","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.2337\/dc23-1135","article-title":"Predictors of \u226515% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1\u20134","volume":"46","author":"Ma\u0142ecki","year":"2023","journal-title":"Diabetes Care"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvag210\/71000795\/bvag210.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/10\/bvag210\/71000795\/bvag210.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/10\/bvag210\/71000795\/bvag210.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:16:40Z","timestamp":1790673400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvag210\/8788471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvag210","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,3]]},"article-number":"bvag210"}}